19-Oct-2024 9:27 AM CST - Morningstar Defined Outcome ETF Primer Recent market volatility has increased demand for defined outcome ETFs, also known as target outcome ETFs, which offer downside protection in exchange for capped upside potential. These funds have ...
17-Oct-2024 5:33 AM CST - The Motley Fool 3 ETFs to Buy for a Lifetime of Passive Income Daniel Foelber (Vanguard Energy ETF): The energy sector is known for its volatility and sensitivity to oil and gas prices. Whereas when investors think about safe stocks that can generate a lifetime of passive income, they probably think of stodgy consumer-facing companies like Coca-Cola or Procter & Gamble.
16-Oct-2024 5:06 AM CST - The Motley Fool Why I'm Considering Leaning Heavily Into Pfizer As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The company's strong cash flow supports continued dividend growth and business reinvestment. For those willing to weather near-term volatility, Pfizer could deliver strong total returns in the years ahead.
19-Oct-2024 9:27 AM CST - Morningstar Defined Outcome ETF Primer Recent market volatility has increased demand for defined outcome ETFs, also known as target outcome ETFs, which offer downside protection in exchange for capped upside potential. These funds have ...
17-Oct-2024 5:33 AM CST - The Motley Fool 3 ETFs to Buy for a Lifetime of Passive Income Daniel Foelber (Vanguard Energy ETF): The energy sector is known for its volatility and sensitivity to oil and gas prices. Whereas when investors think about safe stocks that can generate a lifetime of passive income, they probably think of stodgy consumer-facing companies like Coca-Cola or Procter & Gamble.
16-Oct-2024 5:06 AM CST - The Motley Fool Why I'm Considering Leaning Heavily Into Pfizer As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The company's strong cash flow supports continued dividend growth and business reinvestment. For those willing to weather near-term volatility, Pfizer could deliver strong total returns in the years ahead.
